Guided Therapeutics’ to Sell Five Additional LuViva® Advanced Cervical Scans to Nairobi County, Kenya for Cervical Cancer Screening Program

Largest population center in East Africa includes approximately
900,000 screening-aged women

NAIROBI, Kenya–(BUSINESS WIRE)–Guided Therapeutics, Inc. (OTCQB: GTHP), a maker of a rapid and painless
testing platform based on its patented biophotonic technology, today
announced that Nairobi County Health Services Sector has agreed to
purchase an additional five LuViva® Advanced Cervical Scans for use in
the agency’s cervical cancer screening program.

The five LuVivas are expected to ship in Q1 2016. The planned purchase
brings to six the number of LuVivas purchased by Nairobi County with an
additional seven units planned for purchase in 2016. When fully
implemented, the County will have the capacity to screen more than
12,000 women per month.

“With its immediate results and ease of use, we believe that LuViva is
the best option for screening for cervical cancer,” said Nairobi
County Chief Officer for Health Dr. Robert Ayisi. “Routine screening,
which leads to early detection, combined with other prevention measures,
is the best way to reduce the incidence of cervical cancer, which is a
major problem in East Africa.”

“We believe that working with governments is the most effective way to
use LuViva for the early detection of cervical cancer and we are pleased
to be working with Nairobi County,” said Gene Cartwright, CEO and
President of Guided Therapeutics. “Management is proud to be on the
front line, helping to address such a serious issue. LuViva is part of
government programs now in Kenya and in Asia and we continue to work
with governments in Asia and Latin America to expand its use as a front
line tool for cervical cancer screening.”

Cervical cancer ranks number one in cancers of women in Kenya. According
to the World Health Organization (WHO) and The International Cancer
Organization (ICO) Information Centre, there are 10.32 million women in
Kenya at risk of developing cervical cancer. The annual number of women
diagnosed with cervical cancer is 2,454, with 1,676 dying every year. It
is estimated that there are 15 new cases of cervical cancer diagnosed
each week in Nairobi County. These statistics show that an estimated
12.7 women out of every 100,000 are affected.

Worldwide, the market for cervical cancer screening and diagnostics, as
currently practiced using cytology (Pap test) for primary screening, is
estimated at $6 billion and is projected to grow to almost $9 billion by
2020. There are about 2.6 billion women aged 15 years and older who are
at risk of developing cervical cancer worldwide.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which may result in eliminating costly, painful and
unnecessary additional testing. LuViva is intended for use with women
who have undergone initial screening and are called back for follow up
with a colposcopy examination, which in many cases, involves taking a
biopsy of the cervix. It has also been used in clinical studies in
Turkey and Nigeria as a means to screen women for cervical cancer where
the availability of infrastructure necessary for Pap and HPV testing is
restricted. The device is used in conjunction with the LuViva® Cervical
Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and
painless testing platform based on its patented biophotonic technology
that utilizes light for the early detection of disease at the cellular
level. The Company’s first product is the LuViva® Advanced Cervical
Scan, a non-invasive device used to detect cervical disease instantly
and at the point of care. In a multi-center clinical trial, with women
at risk for cervical disease, the technology was able to detect cervical
cancer up to two years earlier than conventional modalities, according
to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an
investigational device and is limited by federal law to investigational
use in the U.S. LuViva, the wave logo and “Early detection, better
outcomes” are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
early stage of products in development, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the sufficiency of capital raised in our prior financings and
our ability to realize their expected benefits, the uncertainty of
future capital to develop products or continue as a going concern, the
uncertainty of regulatory approval of products, and the dependence on
licensed intellectual property, as well as those that are more fully
described from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2014
and subsequent filings.

Contacts

Investor and Media Relations Contact:
IRTH Communications
Robert
Haag, 866-976-4784
Managing Partner
gthp@irthcommunications.com
or
Guided
Therapeutics
Bill Wells, 770-242-8723